Apr 16, 2018 - With a key pipeline drug nixed, Incyte has a few more question marks on the horizon than it did before.
Apr 16, 2018 - The Zacks Analyst Blog Highlights: Agios Pharmaceuticals, BioMarin Pharmaceutical, Vertex Pharmaceuticals and Incyte
Apr 13, 2018 - Investor confidence in epacadostat was through the roof, and the drug's phase 3 flop crushed the stock in a big way.
Apr 13, 2018 - Novartis and Alexion announce respective acquisitions of AveXis and Wilson Therapeutics for a pipeline boost. We suggest four stocks as hot acquisition picks this year.
Apr 12, 2018 - Biotech is risky business, and Incyte shareholders have not had a good week after a key drug flopped its phase 3.
Apr 12, 2018 - Find out which of these companies jumped on takeover chatter.
Apr 11, 2018 - A clinical-trial flop with epacadostat isn't the end of the world for Incyte.
Apr 11, 2018 - The biotech sector was in the news last week as shares of Spectrum surged on positive data from a phase II study while Incyte plunged on the failure of melanoma study.
Apr 09, 2018 - Shares of NewLink Genetics Corp. (NLNT) plunged about 42.6% following the news of the failure of Incyte and Merck's phase III combination study for metastatic melanoma.
Apr 09, 2018 - Gabelli & Co issues rating change for INCY